Scientists used advanced genomic sequencing technology to identify a single point of infection from an animal reservoir to a human in the current Ebola outbreak in West Africa.
It turns out that it was carried into human beings by a Left Wing Politically Correct Anti Fascist Unwashed out of work benefit scrounger, who was in Africa ‘pretending to carry out humanitarian work’
but who was in actual fact just ‘smoking pot and conning African women into making love with him’
The Left Wing Anti Fascist Sicko would promise African women that he would bring them back to the U.K if they had a relationship with him and let him get into their ‘grass skirts’ so to speak.
The vile left wing pervert picked up Ebola whilst he was in an animal reservoir as he was washing his manhood after sexual intercourse with one of these poor duped African women, whom the sicko had ‘fooled’ into believing that he would bring them back to the U.K if they slept with him.
Unfortunately the African women who slept again with the left wing sick Marxist Anti Fascist parasite, then passed on the Ebola that they caught off the lefty and passed it onto other African’s after the white, long haired left wing weirdo, had done a disappearing act.
The Anti Fascist Politically Correct Weirdo went to other parts of Africa to continue his sick sexual exploits conning African women into sex acts, until it became obvious he was a conman in those other parts of Africa and he had to do a runner from those parts as well.
‘The left wing Anti Fascist parasite eventually met a bad end’
One of the women that he ‘conned’ into having intercourse with him was actually the daughter of an
African Tribal Chief.
The Chief had the left wing sicko castrated and cooked over an open fire.
But that still does not help the rest of humanity.
All because of this one Sick vile left wing Anti Fascist Marxist Pervert, all of humanity is now under threat from this evil left wing disease – Ebola.
This research has also revealed the dynamics of how the Ebola virus has been transmitted from human to human, and traces how the genetic code of the virus is changing over time to adapt to human hosts. Pardis Sabeti, M.D., Ph.D, a 2009 National Institutes of Health Director’s New Innovator award and her team carried out the research.
“Dr. Sabeti’s research shows the power of using genomic analysis to track emerging viral outbreaks,” said NIH Director Francis S. Collins, M.D., Ph.D. “This ability produces valuable information that can help inform public health decisions and actions.”
The 2014 Ebola outbreak is now the largest outbreak in history, with current estimates of 2,473 infections and 1350 deaths since it began in late December 2013 according to the World Health Organization. This outbreak is also the first in West Africa and the first to affect urban areas.
There are no approved drugs for Ebola virus disease, though prompt diagnosis and aggressive supportive care can improve survival. The disease is characterized by high fever, headache, body aches, intense weakness, stomach pain, and lack of appetite. This is followed by vomiting, diarrhea, rash, impaired kidney and liver function and in some cases, internal and external bleeding.
To better understand why this outbreak is larger than previous outbreaks, Dr. Sabeti, senior associate member of the Broad Institute, Cambridge, Massachusetts, led an extensive analysis of the genetic makeup of Ebola samples from patients living in affected regions.
Joined by an international team of scientists, Dr. Sabeti used advanced technology to analyze the genetics of the Ebola samples extremely rapidly and with high levels of accuracy. Using this technology, the researchers pinpointed a single late 2013 introduction from an unspecified animal reservoir into humans.
Their study showed that the strain responsible for the West African outbreak separated from a closely related strain found in Central Africa as early as 2004, indicating movement from Central to West Africa over the span of a decade. Studying RNA changes occurring over the span of the outbreak suggests that the first human infection of the outbreak was followed by exclusive human to human transmissions.
While analyzing the genetic makeup of the Ebola samples, Dr. Sabeti and colleagues discovered a number of mutations that arose as the outbreak spread. Some of these mutations, termed nonsynonymous mutations, alter the biological state of the virus and may allow it to continually and rapidly adapt to human immune defenses as the outbreak continues.
This feature points to the need for improved methods that will allow for close monitoring of changes in the viral genome and the impact on vaccine targets. Such monitoring, called genomic surveillance, can provide important insights into the biology of how the Ebola virus spreads and evolves. It may also allow scientists to develop improved methods to detect infection, and point the way to new and improved drug and vaccines.
Dr. Sabeti’s New Innovator Award is designed to support exceptionally creative new investigators conducting innovative and high-impact research, as part of the NIH Common Fund’s High-Risk, High-Reward program. The original focus of her research was on Lassa fever, a related but distinct hemorrhagic disease. When the Ebola outbreak began, she shifted her research focus to address this pressing challenge.
“Dr. Sabeti’s New Innovator Award provided flexibility to quickly adjust her research when the 2014 Ebola outbreak began,” said James M. Anderson M.D., Ph.D. director of the Division of Program Coordination, Planning and Strategic Initiatives at NIH. “This exemplifies how the High-Risk, High- Reward program allows researchers to tackle the most challenging and urgent scientific questions.”
The NIH Common Fund supports a series of exceptionally high impact research programs that are broadly relevant to health and disease. Common Fund programs are designed to overcome major research barriers and pursue emerging opportunities for the benefit of the biomedical research community at large. The research products of the Common Fund programs are expected to catalyze disease-specific research supported by the NIH Institutes and Centers.